MYO5B mutations in pheochromocytoma/paraganglioma promote cancer progression
Journal article, 2020

Identification of additional cancer-associated genes and secondary mutations driving the metastatic progression in pheochromocytoma and paraganglioma (PPGL) is important for subtyping, and may provide optimization of therapeutic regimens. We recently reported novel recurrent nonsynonymous mutations in the MYO5B gene in metastatic PPGL. Here, we explored the functional impact of these MYO5B mutations, and analyzed MYO5B expression in primary PPGL tumor cases in relation to mutation status. Immunohistochemistry and mRNA expression analysis in 30 PPGL tumors revealed an increased MYO5B expression in metastatic compared to non-metastatic cases. In addition, subcellular localization of MYO5B protein was altered from cytoplasmic to membranous in some metastatic tumors, and the strongest and most abnormal expression pattern was observed in a paraganglioma harboring a somatic MYO5B:p.G1611S mutation. In addition to five previously discovered MYO5B mutations, the present study of 30 PPGL (8 previous and 22 new samples) also revealed two, and hence recurrent, mutations in the gene paralog MYO5A. The three MYO5B missense mutations with the highest prediction scores (p.L587P, p.G1611S and p.R1641C) were selected and functionally validated using site directed mutagenesis and stable transfection into human neuroblastoma cells (SK-N-AS) and embryonic kidney cells (HEK293). In vitro analysis showed a significant increased proliferation rate in all three MYO5B mutated clones. The two somatically derived mutations, p.L587P and p.G1611S, were also found to increase the migration rate. Expression analysis of MYO5B mutants compared to wild type clones, demonstrated a significant enrichment of genes involved in migration, proliferation, cell adhesion, glucose metabolism, and cellular homeostasis. Our study validates the functional role of novel MYO5B mutations in proliferation and migration, and suggest the MYO5-pathway to be involved in the malignant progression in some PPGL tumors.

Author

Tajana Tesan Tomic

University of Gothenburg

Josefin Olausson

University of Gothenburg

Anna Rehammar

Chalmers, Mathematical Sciences, Applied Mathematics and Statistics

Lily Deland

University of Gothenburg

Andreas Muth

Sahlgrenska University Hospital

University of Gothenburg

K. Ejeskar

University of Skövde

Staffan Nilsson

University of Gothenburg

Chalmers, Mathematical Sciences, Applied Mathematics and Statistics

Erik Kristiansson

Chalmers, Mathematical Sciences, Applied Mathematics and Statistics

Ola Nilsson Wassén

University of Gothenburg

Frida Abel

University of Gothenburg

PLoS Genetics

1553-7390 (ISSN) 1553-7404 (eISSN)

Vol. 16 6 e1008803-

Subject Categories

Cell Biology

Cell and Molecular Biology

Medical Genetics

DOI

10.1371/journal.pgen.1008803

PubMed

32511227

More information

Latest update

8/12/2020